CORDIS
EU research results

CORDIS

English EN

Biosimulation - A New Tool in Drug Development

Objective

International competition in the pharmaceutical industry is increasingly becoming a competition with respect to the ability to understand complex biological processes and exploit the rapidly growing amount of biological information. The methods that are currently applied in the development of new medicines suffer from the lack of effective means to evaluate, combine, and accumulate biological knowledge. Essential improvements must involve the use of computational models that can provide a dynamic and more quantitative description of the relevant biological, pathological, and pharmacokinetic processes. We propose to establish a Network of Excellence that can restructure and strengthen the area of biosimulation by focusing on the development of professional, physiologically based models that can help the pharmaceutical industry develop safe and effective drugs at significantly lower costs. The modelling approach is strongly recommended by the American Food and Drug Administration that already uses mathematical models in its evaluation of applications for drug approval. Academic institutions in Europe have significant expertise in biological modelling, and several groups are individually at the research front in their specific areas. At the present, however, the research is strongly fragmented, and the industry itself has relatively few qualified experts in the field. The Network will provide a new forum for collaboration across disciplinary boundaries as well as between industry and academia. The BioSim Network involves 26 leading academic groups, 9 small and medium-sized enterprises, 1 large pharmaceutical industry, and the Danish, Spanish, Dutch, and Swedish regulatory agencies. The Network collaborates with the European Federation for Pharmaceutical Sciences (EUFEPS).

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

TECHNICAL UNIVERSITY OF DENMARK

Address

Anker Engelundsvej 101
Kgs. Lyngby

Denmark

Administrative Contact

Erik MOSEKILDE (Professor)

Participants (38)

Sort alphabetically

Expand all

VRIJEUNIVERSITEIT AMSTERDAM/FACULTEIT AARD- EN LEVENSWETENSCHAPPEN/IMC

Netherlands

THE CHANCELLOR, MASTER AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

PHILIPPS-UNIVERSITAET MARBURG

Germany

UNIVERSITY OF MANCHESTER

United Kingdom

UNIVERSITAET POTSDAM

Germany

FORSCHUNGSZENTRUM JUELICH GMBH

Germany

LUND UNIVERSITY

Sweden

LINKOEPING UNIVERSITY

Sweden

UNIVERSITE LIBRE DE BRUXELLES

Belgium

UNIVERSITAT DE VALENCIA, ESTUDI GENERAL

Spain

UNIVERSITY OF COPENHAGEN

Denmark

UNIVERSITY OF WARWICK

United Kingdom

UNIVERSITY OF SHEFFIELD

United Kingdom

TECHNISCHE UNIVERSITAET OF DRESDEN

Germany

INSITUTE OF EXPERIMENTAL PHARMACOLOGY, SLOVAK ACADEMY OF SCIENCES

Slovakia

INSTITUTE OF ENZYMOLOGY, HUNGARIAN ACADEMY OF SCIENCE

Hungary

CHARITE UNIVERSITATSMEDIZIN BERLIN, INSTITUTE OF MEDICAL INFORMATICS

Germany

UNIVERSITAT DE LES ILLES BALEARS

Spain

UNIVERSITY OF BORDEAUX 2 - VICTOR SEGALEN

France

UNIVERSITY OF LEEDS

United Kingdom

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EML RESEARCH GGMBH

Germany

SIMCYP LIMITED

United Kingdom

INNETICS AB

Sweden

MXM LABORATORIES SA

France

LAXDALE LIMITED

United Kingdom

SEMGINE GMBH

Germany

FRAUNHOFER-CHALMERS RESEARCH CENTRE FOR INDUSTRIAL MATHEMATICS

Sweden

SOLVO BIOTECHNOLOGY INC.

Hungary

ZEALAND PHARMA A/S

Denmark

NOVO NORDISK A/S

Denmark

DANISH MEDICINES AGENCY

Denmark

AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS

Spain

MEDICINES EVALUATION BOARD

Netherlands

MEDICAL PRODUCTS AGENCY

Sweden

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

THE UNIVERSITY OF EDINBURGH

United Kingdom

UNIVERSITÀ DEGLI STUDI DI PADOVA

Italy

Project information

Grant agreement ID: 5137

  • Start date

    1 December 2004

  • End date

    31 March 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 24 788 000

  • EU contribution

    € 10 700 000

Coordinated by:

TECHNICAL UNIVERSITY OF DENMARK

Denmark